Filing Flows

Filing Flows › Adma Biologics (ADMA) › Next earnings date

Adma Biologics (ADMA) earnings: beat the estimate

Adma Biologics (ADMA) reported on Nov 4, 2026 and beat the EPS estimate: $0.23 against $0.20 (+15.0%). Revenue was $141M for Q3 2026, +5% year over year. It beat the EPS estimate in 80% of the quarters on record.

Last result+15.0% vs estimate
Beat rate80%

The last report

Adma Biologics reported revenue of $141M for the third quarter 2026 (+5% Y/Y), net earnings $49.9M. How it makes money → · Every quarter →

Adma Biologics: EPS against the estimate, last 5 reportsAdma Biologics: EPS against the estimate, last 5 reportsEstimateReported$0.15$0.16Nov 25$0.20$0.22Feb 26$0.20$0.17May 26$0.16$0.17Aug 26$0.20$0.23Nov 26
Latest (Nov 26): Estimate $0.20, Reported $0.23.

Adma Biologics' latest quarter

Adma Biologics, Q3 2026: revenue $141M (+5% year over year), operating margin 48.0%, net earnings $49.9M, operating cash flow $17.4M. The chart follows the revenue to costs, profit and cash.

Questions

Did Adma Biologics beat earnings?

Adma Biologics (ADMA) reported on Nov 4, 2026 and beat the EPS estimate: $0.23 against $0.20 (+15.0%).

When does ADMA report earnings?

The next date is not set yet.

Does Adma Biologics usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.